Investing in cutting edge
Bio-Pharma
02/02/2023
Bioventure and Al Razi Partners up With an Exclusive License Agreement for Oncology Product in KSA Market
Bioventure FZ LLC (“Bioventure”) and Al Razi Pharma Industries (“Al ...
Read More
01/02/2023
Bioventure and AJA Pharma Sign MoU Leveraging Existing Strategic Partnership
Bioventure FZ-LLC and AJA Pharmaceuticals, a subsidiary of Saudi Chemical ...
Read More
01/02/2023
Bioventure and Amman Pharma Sign an Exclusive Licensing Agreement for the Commercialisation of Aflibercept in the Levant region
Bioventure, a subsidiary of GlobalOne Healthcare Holding within Yas Holding’s ...
Read More
27/01/2023
Alvotech and Bioventure announce approval of AVT02 (adalimumab) as Simlandi in KSA
Alvotech (NASDAQ: ALVO) and Bioventure, announced that the Saudi Food ...
Read More
26/01/2023
Bioventure extends its strategic collaboration with Adalvo a leading B2B pharmaceutical company in Europe
Bioventure has extended its strategic partnership with Adalvo, the global ...
Read More
30/06/2022
Bioventure Healthcare FZE and GSK Sign Localisation Agreement to Manufacture Medicines
Global science-led UK healthcare company GlaxoSmithKline (GSK) has announced a ...
Read More
28/06/2022
Geltec Healthcare FZE officially rebrands as Bioventure Healthcare FZE
GlobalOne Healthcare Holding (GHH), our Healthcare Division, announced the rebranding ...
Read More
03/03/2022
Bioventure and Cooper Pharma sign exclusive commercialisation and licensing agreement for Adalimumab in Morocco
Bioventure, a subsidiary of our Healthcare Division, GlobalOne Healthcare Holding ...
Read More
11/01/2022
Yas Holding Acquires Pharma Distributor Al Ittihad Drug Store
GlobalOne Healthcare, Yas Holding’s healthcare investment arm, acquires Pharma Distributor ...
Read More